#Antibody humanization is the process of modifying a non-human antibody, typically from model species such as mice, to make its structure and function more compatible with the human immune system. This involves altering specific regions of the antibody, primarily the framework

It’s intuitive for many of us to view genomes or protein sequences as "languages." We can explain this intuition in many ways, but my favorite explanation comes from our CTO Oded Kalev, who often says it's simply because "we can code these types of data as strings." But what

Let’s talk a bit about #ActiveLearning. Active learning is a machine learning technique where the model can iteratively ask for help in labeling new data points. The beauty of this approach is that it focuses the labeling efforts on the most informative data, improving the

Our CEO, Dov Gertz is speaking today at #AWSReInvent2024, joining Amazon Web Services (AWS), LatentLabsAI and Insilico Medicine for a panel discussion on how #GenerativeAI is revolutionizing #DrugDiscovery. The panel will explore how startups are leveraging AWS to accelerate innovation,

One of the rapidly progressing areas in applying language models to biology is the development of next-generation tokenizers. In contrast to human languages, where words naturally serve as tokens, biological languages like DNA lack clear word boundaries, leading most foundational

Why Do Language Models Struggle with Numerical Reasoning? 🤔 We’ve all seen cases where a model confidently asserts that 9.11 > 9.9. What’s behind these kinds of errors? One key factor is how numbers are represented—and it’s not just about tokenization. 💡 Tokenization and

🚀 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭! 🚀 We’re excited to share that Converge Bio has officially partnered with Remilk , a global leader in animal-free dairy protein production! This collaboration will leverage Converge Bio's

Thoughts from our CSO Iddo Weiner💡: "Generative AI feels almost tailor-made for tackling biotech challenges. Whether it’s designing molecules with precise binding properties, optimizing stability, or refining pharmacokinetics, these tools provide a remarkable foundation for

ICYMI: Exciting Milestone for Converge Bio! We are proud to announce the recent close of our $5.5M seed funding round led by TLV Partners, a major step forward in our mission to transform biological R&D through generative AI. At Converge Bio, we’re at the forefront of

🎙️ Excited to share the recent conversation of our CEO Dov Gertz with Ben from Ben | The SaaS CFO on his podcast! In the podcast they dive into the future of biotech and our work at Converge Bio Tune in here: 🍏 Apple Podcasts:podcasts.apple.com/us/podcast/con… 🎧 Spotify:

💥 AI x Pharma Deals Are Booming — But the Business Model Is Broken 💥 The latest IQVIA data shows over $9.7B in potential cash from AI/ML pharma deals in 2024 alone. Big names. Big money. But there’s a structural flaw in how these deals are done 👇